Summary In the present study we have used the alkaline elution technique to study the effect of misonidazole (MISO) on the initial amount of DNA cross-linking in various normal and neoplastic tissues of C3H mice treated with nitrogen mustard (HN2) in vivo. Tissue samples for analysis of the cross-links were prepared 1 h after injection with HN2 to minimize the effect of subsequent repair processes on the yield of lesions. For mice receiving HN2 alone, the greatest level of cross-linking was found in spleen and jejunum, with the liver showing the lowest level. In animals that had been pretreated with MISO (1 mg g -1, i.p.) for 0.5 h prior to injection with HN2, the amount of cross-linking in the spleen and jejunum was not affected by MISO; however, in all other tissues that were examined, cross-linking was enhanced by MISO to a varying extent depending on the specific tissue. The greatest enhancement was observed in the liver ( x 6) and kidney (x 3.1), both of these tissues showing a greater enhancement than either of the two fibrosarcomas. The potentiation of HN2 cross-linking in a particular tissue correlated well with two cellular processes that are known to be nitroreduction-dependent in vitro, namely, the degree of MISO-induced GSH depletion and the binding of MISO to cellular macromolecules. Thus, the potentiation of cross-linking in normal tissues such as liver and kidney, and by inference in tumours, may be intimately related to the generation and/or accumulation of nitro-reduced MISO metabolites in those tissues.
The potentiation of many antitumour drugs by the hypoxic cell radiosensitizer misonidazole (MISO) is now well documented (McNally, 1982; Millar, 1982; Siemann, 1982 Siemann, , 1984 . However, the mechanisms of chemosensitization, and in particular the role of hypoxia, have not been completely elucidated. Hypoxia during the MISO pretreatment stage has been found to be essential for the in vitro potentiation of all chemotherapy drugs studied to date, including the enhanced cytotoxicity of the bifunctional alkylating agent nitrogen mustard (HN2) to V79 cells (Stratford et al., 1980) and EMT6 tumour spheroids (Twentyman, 1982a (Twentyman, , 1982b . A requirement of hypoxia for MISO enhancement in vivo may explain why tumours generally seem to be sensitized to a greater extent than most normal tissues, although the exact situation regarding the involvement of hypoxia in vivo is unclear. However, Wheeler et al. (1984) recently showed that, at least for the drug BCNU, hypoxia induced by clamping of the leg was clearly critical for sensitization by MISO of a subcutaneous rat 9L tumour.
We recently reported (Murray & Meyn, 1984) that pretreatment of mice with MISO enhanced the in vivo DNA cross-linking activity of HN2 in a murine fibrosarcoma, a tumour that contains a substantial fraction of hypoxic cells (Stone & Milas, 1978; Grdina et al., 1976 (Varnes et al., 1980; Bump et al., 1983) and the binding of MISO to cellular macromolecules (Varghese & Whitmore, 1980; Miller et al., 1982; Bump et al., 1983) , which we supposed to be related to repair inhibition, have been shown in vitro to be mediated by hypoxia; thus, it seemed reasonable to assume that nitroreduction of MISO to generate reactive species, which is thought to require hypoxic conditions (Biaglow, 1981) , would also be a prerequisite for chemosensitization in vivo.
In the present study, we have measured the effect of pretreating mice with MISO on the initial level of HN2-induced DNA cross-linking and on GSH levels in a number of normal tissues and in two fibrosarcomas. The importance of enhanced DNA cross-linking in the sensitization of mammalian cells to alkylating agents has been demonstrated in vitro in the recent studies of Taylor et al. (1982 Taylor et al. ( , 1983 
Materials and methods
Mice and tissue suspensions Details of the specific pathogen-free C3H/Kam mouse colony and of the NFSa tumour, which arose spontaneously in these mice, have been described elsewhere (Ando et al., 1979) . The FSa fibrosarcoma was originally induced by methylcholanthrene (Suit & Suchato, 1967) . Tumours were grown by injecting 5 x 105 cells s.c. into the hind legs of recipient mice, and were used when they reached a mean diameter of 10-12mm. Animals were sacrificed following the treatment protocol, and the relevant tissues were quickly removed and immersed in ice-cold Puck's solution A (PSA) containing 5mM EDTA. Single-cell suspensions were prepared from these tissues as described elsewhere (Meyn & Jenkins, 1983) . To obtain NFSa cells, the viable tumour was excised, finely minced with a razor blade, syringed with 8 ml of PSA through a 15-gauge needle, then filtered through cotton gauze.
Alkaline elution
The alkaline elution technique originally devised by Kohn (1979) for use with in vitro systems has been adapted for use with in vivo systems using a fluorometric DNA assay with the dye Hoechst 33258 (Cesarone et al., 1979; Murray & Meyn, 1983 ). To measure cross-linking using alkaline elution, a constant number of single-strand breaks were introduced into the DNA by irradiating the cell suspensions in vitro on ice with 5Gy of X-rays as discussed previously (Murray & Meyn, 1983) . These 5-Gy irradiated samples consequently eluted much faster than their respective nonirradiated controls. Treatment of mice with HN2 produced cross-links in the DNA, which after irradiation with 5 Gy in vitro, resulted in a slower rate of elution for these samples than for the 5-Gy control with no drug treatment. The DNA lesions produced after treatment of cells with HN2 in vitro have been shown to be of two types, namely proteinase Kresistant and -sensitive cross-links; these are presumably DNA-DNA interstrand and DNAprotein cross-links respectively (Ewig & Kohn, 1977; Ross et al., 1978) . We previously found (Murray & Meyn, 1984) In order to test whether MISO (Murray & Meyn, 1984) ; those for NFSa and spleen were also linear (data not shown) within the concentration range studied (0-4mg kg-1). Based on the observed linearity of these dose-responses, the enhancement of DNA cross-linking by pretreatment with MISO (Table I and Figure 2 ) appears to represent true dosemodification, and the calculated "enhancement factor" is therefore independent of the HN2 dosage over this dose range. Control experiments using alkaline elution analysis (data not shown) showed that treatment with MISO alone for up to 1.5 h produced no detectable strand-breakage in DNA isolated from any of the tissues studied except in the case of NFSAa, where a small number of breaks were observed. Likewise, neither HN2 alone, nor MISO plus HN2, caused any DNA strand-breakage 1 h after injection with HN2. As we reported previously, (Murray & Meyn, 1984) Biaglow (1981) . It should be noted that the capacity of a cell to reduce nitro compounds to the one electron reduction product, the nitro radical anion, does not depend on the state of oxygenation; rather, under aerobic conditions, further reduction of this species is inhibited by reaction with oxygen. For the remainder of this discussion, the term "nitroreduction" will be taken to imply that other processes, such as the addition of further electrons to the MISO radical anion, can efficiently compete with molecular oxygen. In the extreme case, a further five electrons may be added to generate the 2-aminoimidazole derivative (Biaglow, 1981) .
The possible relationship between the removal of nonprotein thiols and the enhancement of the initial level of HN2-induced DNA lesions in vivo can be examined by comparing the degree of GSH depletion in a particular tissue 1 h after injection with MISO (Table II) with the cross-linking enhancement factor (Table I) (Murray & Meyn, 1984) . The data for five tissues, liver, FSa, NFSa, kidney and spleen, are shown in the form of a correlation plot in Figure 3a . Linear regression analysis of these data shows a strong correlation between lowering of GSH levels by MISO and enhancement of the initial yield of DNA cross-linking induced by HN2 (correlation coefficient 0.99). These results support our previous conclusion, based on the effect of the GSHdepleting reagent diethyl maleate on HN2 crosslinking in the FSa tumour, that the initial phase of cross-linking enhancement (0-1 h) is primarily due to MISO-induced depletion of GSH (Murray & Meyn, 1984) .
Since both chemosensitization and GSH depletion in vitro would appear to require anaerobic nitroreduction of MISO, a similar requirement for hypoxia would be anticipated in vivo. In a recent study of X-ray-induced DNA strand-breaks in mice, the observed response was explained by assuming that normal tissues are radiobiologically hypoxic to varying degrees (Meyn & Jenkins, 1983) . Tissues such as spleen and bone marrow, which were more responsive to X-rays, were considered to be relatively well oxygenated, whereas resistant tissues such as liver, jejunum, and FSa showed a response consistent with their being (Table I) with an estimate of relative hypoxia, based on the X-ray response from Meyn & Jenkins (1983) for a particular tissue, suggests little correlation between these events. For example, although bone marrow appeared from its reponse to X-rays to be relatively well oxygenated, it was enhanced by a factor of almost 2 (Table I) , whereas jejunum, a relatively more hypoxic tissue, showed no enhancement. Thus, although normal tissue hypoxia may be important in the response to X-rays, additional factors may play a more important role in chemosensitization. This apparent difficulty in resolving the involvement of hypoxia per se in the chemosensitization of normal tissues in vivo may be due to the metabolism of MISO at non-hypoxic loci, as discussed below.
In addition to the interaction between MISO and GSH, the binding of MISO-metabolites to cellular macromolecules also requires nitroreduction, as demonstrated in anaerobic mammalian cells in vitro. Miller and co-workers (1982) have recently reported that the binding of 14C-MISO is 55 times more rapid in EMT-6 tumour cells made hypoxic in vitro than in well-oxygenated cells. This same requirement would also be expected in vivo, suggesting that binding and accumulation of MISO metabolites in tissues is a measure of the degree of nitroreduction occurring in those tissues. Chin & Rauth (1981) have demonstrated extensive metabolism and retention of 14C-labelled MISO in mouse liver, and to a lesser extent in kidney, whereas little evidence of metabolism was seen in brain or spleen. Analysis of the metabolic products showed the presence of a considerable proportion of the amino derivative in both liver and kidney, suggesting that appreciable nitroreduction occurred in these tissues. Garrecht & Chapman (1983) have also studied the clearance of 14C-labelled MISO from mouse tissues, and again marked retention of 14C was observed in the liver, as well as in regions of tumours considered to be hypoxic. Retention by liver was suggested to be related to unique biochemical activities involved in drug detoxification rather than to the existence of a low oxygen tension in liver relative to other normal tissues. All of the other normal tissues retained small but measurable levels of radioactivity even up to 72 h after MISO injection.
In Figure 3b , 1 h cross-linking enhancement factors (data from (Millar, 1982; Siemann, 1982) , and may be an especially important mechanism in the case of the drugs CCNU (Lee & Workman, 1983) and melphalan (Clutterbuck et al., 1982; Hinchliffe et al., 1983) . Brown & Hirst (1982) showed that a protocol involving multiple low doses of MISO, designed to mimic human serum levels of the drug, still sensitized the RIFI sarcoma to both melphalan and cyclophosphamide, with no associated increase in normal tissue toxicity as measured by white blood cell counts, bone marrow colony-forming units, or testicular damage. Chronic low-dose MISO protocols were subsequently shown to have no effect on melphalan serum levels (Hinchliffe et al., 1983) , suggesting that pharmacokinetic alterations in mice may be unique to the use of acute highdosage MISO, and thus are unlikely to be important in the clinical situation. In the case of HN2, MISO-induced pharmacokinetic changes probably do not contribute significantly to the observed sensitization (Murray & Meyn, 1984 ). This conclusion is further supported by the present data, since the absence of sensitization to HN2 in tissues such as spleen and jejunum is inconsistent with a generalized alteration of serum pharmacokinetics being a major mechanism. This is not to suggest that pharmacokinetic effects may not be important in the enhancement of other cross-linking agents after acute high doses of MISO. Workman et al. (1983) have shown that one action of MISO is to inhibit the metabolism of other cytotoxic drugs in the liver, particularly those pathways involving cytochrome P450. We previously examined the effect of MISO on melphalan-induced DNA crosslinking in mouse tissues (Murray & Meyn, 1983) , and reported enhancement factors of 1.5 for the two normal tissues (spleen and jejunum) that showed no enhancement with HN2. For spleen, which appears to be relatively well oxygenated and showed no MISO-induced GSH depletion, this result was initially surprising. However, it now appears that the sensitization of spleen and jejunum to melphalan is due largely to pharmacokinetic effects associated with this drug as discussed above.
The observation of extensive damage to DNA in normal tissues after treatment with the alkylating agent alone is not surprising in view of the known toxicity pattern characteristic of HN2. The normal tissue toxicities of HN2 largely parallel those of other agents that are specific for proliferating cells, e.g. damage to the haematopoietic and immunological systems and to the gastrointestinal mucosa (Ochoa, 1969; Calabresi & Parks, 1980) . Previous studies have failed to show a selective uptake of alkylating agents in those tissues showing severe injury (bone marrow, lymph nodes, intestinal epithelium or tumour tissues) (Ochoa, 1969) . This lack of selective drug localization in tumours led Ochoa (1969) to conclude that any therapeutic advantage with HN2 must reside in factors other than distribution. The present data confirm that this lack of selective tumour effect is also evident at the molecular lesion level; the tissues showing the greatest level of DNA damage were the jejunal mucosa and spleen, while bone marrow showed a much lower level of cross-linking comparable to that measured in the two tumours. This apparent lack of correlation between toxicity and the level of DNA damage may reflect the fact that in the present study we have measured an effect that represents an average of all of the cells in a particular tissue, regardless of heterogeneity; the toxic effects of the drug, however, are probably determined primarily by the response of the clonogenic cells which may only represent a small fraction of the total population.
In summary, we have shown that while pretreatment of mice with MISO potentiates HN2-induced DNA cross-linking in two fibrosarcomas in vivo, the potential clinical application of chemosensitization is unclear, since four of the six normal tissues examined were also enhanced to varying degrees. In fact, DNA damage in liver was potentiated to a greater extent than in either tumour, although there was only a very low level of cross-linking in this tissue after treatment with HN2 alone. Assuming that the mechanism and pattern of sensitization is similar for other antitumour agents, enhancement of hepatotoxicity and nephrotoxicity might be expected to be potentially limiting factors in the application of MISO in combination with certain drugs, and should be further investigated with biological end-points for impaired organ function. It should be noted that the present study employed a particular scheduling and dosage of the two drugs based on a previous study (Murray & Meyn, 1984) . Both thiol depletion (Varnes et al., 1980) and binding of MISO to cellular macromolecules (Varghese & Whitmore, 1980; Miller et al., 1982) are time-dependent processes, and therefore drug scheduling is likely to be an important aspect of chemosensitization. In particular, varying the time between injection of MISO and HN2 could result in sensitization of tissues not affected in the present study and/or abrogate the degree of sensitization that was observed.
